MedTrace Logo

Dexmedetomidine and Swallowing Function

NCT03390972 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-01-05

No results posted yet for this study

Summary

The purpose of the study is to evaluate the impact of dexmedetomidine on swallowing function in healthy volunteers using combined pressure and impedance recordings. Furthermore, two different concentrations of dexmedetomidine will be studied to find out whether any posible impact of dexmedetomidine on swallowing function is dose-dependent.

Conditions

  • Deglutition

Interventions

DRUG

Placebo

Placebo (NaCl 0.9%) TCI infusion

DRUG

Dexmedetomidine

Dexmedetomidine TCI 0.6 ng/ml and 1.2 ng/ml

Sponsors & Collaborators

  • Region Örebro County

    lead OTHER

Principal Investigators

  • Johanan Savilampi, Phd · Department of Anaesthesiology and Intensive Care, Örebro University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-22
Primary Completion
2018-04-11
Completion
2018-04-11

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03390972 on ClinicalTrials.gov